Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL v randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 315, Issue 9, 2016, Pages 898-907

  Lingvay, Ildiko ^a,b   Manghi, Federico Perez ^c   García Hernández, Pedro ^d   Norwood, Paul ^e   Lehmann, Lucine ^f   Tarp Johansen, Mads Jeppe ^f   Buse, John B ^g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Division of Cardiology   (Argentina)

^d HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^e Valley Research   (United States)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; INSULIN GLARGINE; METFORMIN; ANTIDIABETIC AGENT; INSULIN DEGLUDEC; LONG ACTING INSULIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALCITONIN BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; SIDE EFFECT; TREATMENT DURATION; TREATMENT WITHDRAWAL; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; MIDDLE AGED;

DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; WEIGHT GAIN; WEIGHT LOSS;

EID: 84959284398     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.1252     Document Type: Article

References (21)

1. Curtis B, Lage MJ. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ. 2014;17(1):21-31.
2. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29(7):e13-e20.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149.
4. Clinicaltrials.gov. A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in subjects with type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT02420262. Accessed December 10, 2015.
5. US Department of Health and Human Services. Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. http://www.fda.gov/downloads/Drugs/../Guidances/ucm071624.pdf. Accessed February 4, 2016.
6. Abdi H. Holm's sequential Bonferroni procedure. In: Salkind N, ed. Encyclopedia of Research Design. Thousand Oaks, CA: Sage; 2010.
7. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf. Accessed February 4, 2016.
8. Luo J, Qu Y. Analysis of hypoglycemic events using negative binomial models. Pharm Stat. 2013; 12(4):233-242.
9. O'Kelly M, Ratitch B. Clinical Trials With Missing Data: A Guide for Practitioners. West Sussex, United Kingdom: John Wiley & Sons; 2014.
10. Koch GG. Comments on "current issues in noninferiority trials" by Thomas R. Fleming, statistics in medicine. Stat Med. 2008;27(3):333-342.
11. Keene ON, Roger JH, Hartley BF, Kenward MG. Missing data sensitivity analysis for recurrent event data using controlled imputation. Pharm Stat. 2014; 13(4):258-264.
12. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228-2234.
13. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;62(164):6-10.
14. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689.
15. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ. 2006;32(6):910-917.
16. Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med. 2005;20(5):479-482.
17. Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? results from the MODIFY survey. Diabetes Educ. 2011;37(1):111-123.
18. Liu FP, Dong JJ, Yang Q, et al. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: a systematic review and meta-analysis. J Diabetes. 2015;7(3):322-328.
19. Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224-1230.
20. Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046-2055.
21. Buse JB, Vilsbøll T, Thurman J, et al; NN9068-3912 (DUAL-II) Trial Investigators. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926-2933.